Table 1.
Baseline characteristics.
| Pravastatin group n = 793 |
Control group n = 785 |
|
|---|---|---|
| Age, years | 66.1 ± 8.4 | 66.4 ± 8.6 |
| Male, n (%) | 545 (68.7) | 542 (69.0) |
| Height, cm | 160.4 ± 8.8 | 160.1 ± 8.6 |
| Weight, kg | 61.5 ± 10.2 | 60.7 ± 10.1 |
| Body mass index, kg/m2 | 23.8 ± 3.1 | 23.6 ± 3.0 |
| Total cholesterol, mmol/L | 5.45 ± 0.62 | 5.42 ± 0.64 |
| HDL cholesterol, mmol/L | 1.39 ± 0.41 | 1.37 ± 0.41 |
| LDL cholesterol, mmol/L | 3.35 ± 0.63 | 3.35 ± 0.64 |
| Triglyceride, mmol/L | 1.61 ± 0.85 | 1.60 ± 0.82 |
| Hypertension, n (%) | 596 (75.2) | 604 (76.9) |
| Systolic blood pressure, mm Hg | 137.3 ± 17.6 | 136.9 ± 18.0 |
| Diastolic blood pressure, mm Hg | 79.3 ± 11.6 | 79.4 ± 10.9 |
| Diabetes mellitus, n (%) | 185 (23.3) | 184 (23.4) |
| Fasting blood glucose, mmol/L | 6.56 ± 2.38 | 6.49 ± 2.17 |
| Coronary artery disease, n (%) | 37 (4.7) | 44 (5.6) |
| Chronic kidney disease, n (%) | 195 (24.6) | 183 (23.3) |
| Creatinine, md/dL | 0.81 ± 0.21 | 0.80 ± 0.21 |
| Smoking habit | ||
| Smoker, n (%) | 426 (53.7) | 420 (53.5) |
| Non-smoker, n (%) | 358 (45.1) | 352 (44.8) |
| Unknown, n (%) | 9 (1.1) | 13 (1.7) |
| Use of antiplatelet agents, n (%) | 723 (91.2) | 715 (91.1) |
| Ischemic stroke subtype | ||
| Atherothrombotic infarction, n (%) | 195 (24.6) | 206 (26.2) |
| Lacunar infarction, n (%) | 502 (63.3) | 504 (64.2) |
| Infarction of undetermined etiology, n (%) | 96 (12.1) | 75 (9.6) |
No parameters were significantly different between the pravastatin and control groups.